Application of Affinity Selection/Mass Spectrometry to Determine the Structural Isomer of Parnafungins Responsible for Binding Polyadenosine Polymerase

Citations Over TimeTop 22% of 2008 papers

Abstract

To discover antifungal treatments that possess the desired characteristics of broad spectrum activity, a strong safety profile, and oral bioavailability, new discovery strategies must be implemented to identify structural classes of molecules capable of combating these microorganisms. One such technique that has been implemented is the Candida albicans Fitness Test, a whole cell screening platform capable of delineating the mechanism of action of compounds that demonstrate activity against the clinically relevant pathogenic fungus, C. albicans. Screening crude natural product extracts with this technology has resulted in the identification of a novel family of antifungal natural products, named the parnafungins, which inhibit the enzyme polyadenosine polymerase (PAP), a key component of the mRNA cleavage and polyadenylation complex. Owing to the rapid interconversion of the structural and stereoisomers of the parnafungins at neutral pH, the determination of the structural isomer with the highest affinity for PAP with standard biochemical assays has not been possible. Herein, we present an application of affinity-selection/mass spectrometry (AS-MS) to determine that the "straight" parnafungin structural isomer (parnafungin A) binds preferentially to PAP compared to the "bent" structural isomer (parnafungin B).

Related Papers

• → Mucins Suppress Virulence Traits of Candida albicans(2014)133 cited
• → In vitro outcomes of quercetin on Candida albicans planktonic and biofilm cells and in vivo effects on vulvovaginal candidiasis. Evidences of its mechanisms of action(2023)21 cited
• → In vitro Antagonistic Activity of Candida albicans against Filamentous Fungi(2015)4 cited
• RESEARCH OF HUMORAL IMMUNITY AGAINST CANDIDA ALBICANS INFECTION(2002)
• Лечение кандидемий, вызванных Candida albicans и Candida non-albicans, у больных с опухолями системы крови(2019)